Influenza Market Analysis Report 2025 with Forecast to 2029: Government Support and Funding for Novel Therapies and Diagnosis Fueling Developments

Yahoo

4 days ago

Global Influenza Market to Hit USD 12.8 Billion by 2029: A Comprehensive AnalysisThe global influenza market, valued at USD 9 billion in 2024, is anticipated to grow at a CAGR of 7.2%, reaching USD 12.8 billion by 2029. This growth is driven by the vaccine segment, the most effective preventive measure against influenza's severe effects. The report offers a thorough examination of market trends, including vaccines, diagnostics, and therapeutics, with insights into regional dynamics and competitive landscapes. Key players such as Danaher Corp., Sanofi, and Abbott are highlighted, alongside detailed analyses using Porter's Five Forces and PESTLE models. SEO keywords include global influenza market, influenza vaccines, diagnostics, and market growth.
Influenza Market
Dublin, June 10, 2025 (GLOBE NEWSWIRE) -- The "Influenza Market 2025" report has been added to ResearchAndMarkets.com's offering.The Influenza Market was valued at USD 9 Billion in 2024, and is projected to reach USD 12.8 Billion by 2029, rising at a CAGR of 7.2%. The vaccines segment dominated the global influenza market in 2023. Because influenza vaccines are the most effective method for lowering the risk of contracting influenza and suffering its subsequent effects, the market for this segment is growing. Influenza comes in four varieties: A, B, C and D. Seasonal epidemics are caused by the infectious influenza A and B viruses.
Most people recover from fever and other symptoms within a week without medical intervention. Nevertheless, influenza can result in fatalities or severe illness, particularly in high-risk populations. Seasonal influenza spreads quickly and easily in crowded places like schools and nursing homes, so receiving a vaccination as soon as possible is critical. Based on vaccine type, the segment is further subdivided into inactivated and liveattenuated vaccines.The market for influenza diagnostics has been segmented into rapid tests and conventional lab tests based on diagnostic type. Increased R&D efforts are being made to detect and diagnose influenza more accurately due to its increasing global prevalence. Research is focusing on developing quicker and more precise diagnostic tools for influenza viruses, which will expand the market.Antiviral drugs approved for influenza treatments are discussed in the therapeutic segment. These medications may lessen the likelihood of complications, lessen the severity of symptoms and shorten the course of the illness. These drugs include oseltamivir (Tamiflu), zanamivir (Relenza), peramivir (Rapivab) and baloxavir marboxil (Xofluza).Report ScopeThis report presents qualitative and quantitative data on the current dynamics impacting the global influenza market. It examines the history of various flu pandemics, disease burden and vaccine coverage in several countries. The report thoroughly evaluates the market for influenza vaccines, therapeutics and diagnostics.Analyses of the most popular products, clinical trials, new product approvals and emerging technologies are also included in the report. The demographics of the major regions - North America, Europe and Asia-Pacific - and their growth prospects are summarized. The profiles of leading companies and the strategies of international businesses involved in the influenza sector are also discussed.The market size for influenza is categorized into three product segments: vaccines, therapeutics and diagnostics. Vaccines are further segmented into inactivated vaccines and live-attenuated vaccines. Diagnostics are divided into rapid and conventional lab tests. Additional growth potential and forecast data are addressed for the influenza market in each product segment for every region.For market estimates, data are provided for 2023 as the base year, 2024 as the estimated year and forecast from 2025 through 2029.The report includes:
55 data tables and 70 additional tables
An updated overview and in-depth analysis of the global influenza market
Analyses of the global market trends, with sales data from 2021-2024, and projections of compound annual growth rates (CAGRs) through 2029
Estimates of the actual market size and revenue forecasts, and a corresponding market share analysis by product segment, and region
Discussion of the role of major vaccine providers and companion products approved for a wide variety of influenza testing platforms, including adenovirus, SARS, parainfluenza, coronavirus and human metapneumovirus (hMPV)
Analysis of the market opportunities through the Porter's Five Forces model and PESTLE analysis, taking into consideration the prevailing micro- and macro environmental factors
Insight into the influenza industry structure, government regulations, and key development issues
Analysis of the key patent grants and IP aspects
A discussion of the industry's ESG challenges and practices of the industry
Analysis of the competitive landscape, featuring the leading participants, their current market rankings, and their market shares
Profiles of the leading companies, including Danaher Corp., Sanofi, CSL, La Roche Ltd., and Abbott
Key Attributes:
Report Attribute
Details
No. of Pages
188
Forecast Period
2024 - 2029
Estimated Market Value (USD) in 2024
$9 Billion
Forecasted Market Value (USD) by 2029
$12.8 Billion
Compound Annual Growth Rate
7.2%
Regions Covered
Global
Key Topics Covered: Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Chapter 2 Market Overview
Overview
Pandemic Scenario
Porter's Five Forces Analysis in the Influenza Vaccines Market
Supply Chain Analysis
Vaccine Development
Vaccine Manufacturing
Storage and Inventory Management
Distribution
Administration and Immunization
Macroeconomic Factors Analysis
Impact of U.S.-China Trade War
Global Economic Growth
Demographic Trends
Public Health Crises and Pandemics
Chapter 3 Market Dynamics
Market Dynamics
Key Takeaways
Market Drivers
Development of Rapid Tests and Molecular Technologies
Government Support and Funding for Novel Therapies and Diagnosis
Rising Public Awareness About Flu Vaccines
Market Restraints
Therapeutic Market Dominated by Limited Suppliers
High Cost Associated with Storage and Supply of Flu Vaccines
Market Opportunities
Robust Pipeline of Influenza Vaccines
Demand for Improved Prevention, Treatment and Vaccine Accessibility
Chapter 4 Regulatory Landscape
Overview
Regulatory Aspects of Influenza Vaccines
Use of Trivalent Influenza Vaccines for the 2024-2025 U.S. Influenza Season
Influenza Vaccines Approved by EMA
Regulatory Scenario of Influenza Drugs
Approval Process of Influenza Detection Kit
Sensitivity
Specificity
Chapter 5 Emerging Trends and Pipeline Analysis
Overview
Advance in Influenza Diagnosis
SHINE Technology
Electrochemical Biosensors
Wearable Lab-on-a-Chip Devices
Quantum Dots and Fluorescent Nanoparticles
Role of AI in Influenza Diagnosis
Emerging Technologies in Influenza Vaccines
Universal Influenza Vaccine
mRNA-based Influenza Vaccines
Nanotechnology-based Vaccines
Patch-based Vaccines
Advances in Influenza Therapeutics
Nanoparticle-based Therapies
Potential Drug Agents in Clinical Trials
Patent Analysis
Key Takeaways
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Global Influenza Market by Product Segment
Influenza Diagnostics
Influenza Vaccines
Influenza Therapeutics
Geographic Breakdown
Key Takeaways
North America
Europe
Asia-Pacific
Rest of World
Chapter 7 Competitive Intelligence
Company Share Analysis of the Influenza Vaccines Market
Company Share Analysis of Influenza Diagnostics Market
Company Share Analysis of Influenza Therapeutics Market
Venture Fundings and Investments Landscape
Key Developments in Market
Chapter 8 Sustainability in Influenza Market: ESG Perspective
Overview
ESG Risk Ratings
Conclusion
Chapter 9 AppendixCompanies Featured
Abbott
AstraZeneca
BD
Biocryst Pharmaceuticals Inc.
CSL
Daiichi Sankyo Co. Ltd.
Danaher Corp.
F. Hoffmann-La Roche Ltd.
GSK PLC
Hologic Inc.
Quidelortho Corp.
Sanofi
Sekisui Diagnostics
Thermo Fisher Scientific Inc.
Viatris Inc.
For more information about this report visit https://www.researchandmarkets.com/r/wdn3a2
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
Influenza Market
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager [e-mail] For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call [phone]